logo-loader
viewDeltex Medical Group plc

Deltex Medical’s Doppler monitoring technology praised in CEP report

medical_chart350_4c18cb9160c45.jpg

Deltex Medical Group (AIM: DEMG), specialised in oesophageal Doppler monitoring, has noted the market review "Haemodynamic monitoring systems" published by Centre for Evidence-based Purchasing (CEP) along with a corresponding buyers' guide.

It cited the review as saying that "cardiac output monitoring is becoming standard practice in many surgical procedures and critical care settings" and that "in the operating theatre and post-operative care, only the use of oesophageal Doppler ultrasound has a strong evidence base to demonstrate improved clinical outcomes".

The buyers' guide summarized the various technologies available and analysed their perceived strengths and weaknesses: in respect of ODM it notes “strong evidence to support improved patient outcomes in peri-operative settings.”

“The Centre for Evidence-based Purchasing's new guides are timely. They highlight clearly both that there is a robust evidence base supporting the wide-scale adoption of ODM in intra-operative care and that this evidence base is unique to ODM,” said Deltex chief executive Ewan Phillips.

Deltex Medical manufactures and markets the CardioQ-ODM system. It comprises a monitor and a single patient disposable probe. The probe is placed into the oesophagus through either the mouth or nose and the tip positioned facing the adjacent descending aorta. A low frequency ultrasound signal, generated by the monitor, is bounced off the blood travelling down the aorta and the Doppler principle is used to determine the velocity of the blood flow, expressed in distance per cardiac cycle - 'Stroke Distance'. The monitor also calculates the amount of time that blood is flowing down the aorta as a proportion of a cardiac cycle - 'Flow Time'.

The CardioQ-ODM helps patients by enabling doctors to reduce the complications that arise from a medical condition that is common to almost all patients having surgery and many others in intensive care or arriving in the accident and emergency department. This condition is known as hypovolaemia - a reduction in circulating blood volume - and in surgical patients arises as a direct consequence of the combined effects of pre-operative starvation, the anaesthetic agents and the blood and fluid losses associated with the surgical procedure itself.

Quick facts: Deltex Medical Group plc

Price: 1.7 GBX

AIM:DEMG
Market: AIM
Market Cap: £8.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Sweet Earth Holdings goes public listing on the CSE under...

Sweet Earth Holdings (CSE: SE) CEO Peter Espig and CFO Chris Cooper joined Steve Darling from Proactive Vancouver to discuss the company that operates a large facility in Oregon which is the start of their process of going to seed to sale. Espig talks about all aspects of the company...

1 hour, 25 minutes ago

2 min read